GET DAILY SIGNALSWhy Is Verastem (VSTM) Stock Down -10.45% Today?
Key Takeaways
- VSTM shares fell roughly 10.45% in Thursday's session, trading near $8.40 versus a prior close of $9.38.
- The decline extends a sell-off triggered by third-quarter 2026 results that missed Wall Street's expectations on both earnings and revenue.
- Sequential softness in the AVMAPKI FAKZYNJA CO-PACK launch and a "more gradual" sales outlook weighed on investor sentiment.
- Positive VS-7375 KRAS G12D clinical data and a $250 million financing provided offsets but failed to stem the slide.
- Traders are watching upcoming Phase 3 trial milestones, a February 2027 PDUFA date, and a planned CEO transition.
- For more detail on Price Targets, Earnings, and Forecast, explore Verastem's dedicated pages.
- Discover the strongest-performing strategies right now on the Trending AI Robots page.
Opening Summary
Verastem, Inc. (VSTM), a Needham, Massachusetts-based oncology biotech focused on RAS/MAPK pathway-driven cancers, extended its post-earnings decline on Thursday, with shares dropping about 10.45% to roughly $8.40 from a prior close of $9.38. The move lower follows the company's third-quarter 2026 earnings report, released after Tuesday's close, which showed a wider-than-expected loss and a revenue miss alongside cautious commentary on the trajectory of its AVMAPKI FAKZYNJA CO-PACK commercial launch. The market's reaction reflects disappointment over slowing sequential sales momentum, even as the company's clinical pipeline drew renewed attention.
Earnings Miss and Softer Commercial Momentum
The primary catalyst behind the sell-off was Verastem's third-quarter results. The company reported a net loss of $0.74 per share, well short of the roughly $0.44 per-share loss analysts had anticipated. Revenue came in at $24.01 million, below the approximately $28.45 million consensus, as the AVMAPKI FAKZYNJA CO-PACK franchise delivered a sequential decline to $24.0 million from $25.1 million in the second quarter. Management attributed the slowdown in new patient starts to seasonal headwinds and evolving commercial dynamics, and signaled a "more gradual sales ramp" in recurrent low-grade serous ovarian cancer (LGSOC). That reset of near-term expectations is the key driver behind the share-price reaction.
Rising R&D Spend Weighs on the Bottom Line
Investors also digested a sharp increase in operating expenses. Research and development spending climbed to $68.8 million in the quarter, up significantly year over year, as Verastem advanced three registration-directed Phase 2 trials for its VS-7375 program. Total operating expenses nearly doubled to $99.2 million, widening the non-GAAP adjusted loss to $72.8 million from $39.1 million a year earlier. While the expanded investment is designed to fund pivotal studies in pancreatic, colorectal, and non-small cell lung cancer, the resulting cash burn contributed to the negative tone around the stock.
Pipeline Progress and Balance-Sheet Support
The earnings-driven move was not entirely one-sided. Verastem highlighted compelling early VS-7375 data in KRAS G12D-mutated cancers, including confirmed response rates of roughly 50% in second-line pancreatic cancer, and secured FDA alignment on a first-line pancreatic Phase 3 trial design. The company also received priority review for a new blister-pack formulation of AVMAPKI, with a PDUFA date in February 2027, and raised approximately $250 million in an October public offering, extending its cash runway into the first half of 2028. These positives, however, were not enough to offset investor focus on the softer commercial quarter.
Market Context and Trading Activity
Trading activity was heavy relative to typical sessions, with millions of shares changing hands during the day as the stock broke below its prior range and approached its 50-day moving average near $8.32. As a small-cap biotechnology name with a notable short interest position, Verastem tends to exhibit outsized volatility around binary catalysts such as earnings. The decline was consistent with risk-off pressure concentrated in the stock itself rather than a broad sector move, reflecting a company-specific reaction to the quarter's results and revised commercial guidance.
What Comes Next for VSTM
Looking ahead, investors will monitor the rollout of the blister-pack formulation ahead of the February 2027 PDUFA decision, the initiation of the first-line pancreatic cancer Phase 3 trial expected by year-end 2026, and initial data readouts across the VS-7375 program scheduled through 2027. The planned CEO transition, with Michael P. Bailey assuming the role on January 1, 2027, adds an element of execution risk during a pivotal period. Key uncertainties include the pace of LGSOC adoption, intensifying competition in the KRAS G12D space, and the company's ability to convert pipeline momentum into durable commercial growth.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of algorithmic trading bots covering thousands of tickers, with strategies that vary by approach, timeframe, performance metrics, and the symbols they trade. Only the strongest performers are featured in this rotating selection. Explore the page to see which AI strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
VSTM in upward trend: price may jump up because it broke its lower Bollinger Band on November 06, 2026
VSTM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 36 cases where VSTM's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 60 cases where VSTM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
VSTM moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where VSTM advanced for three days, in 205 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VSTM as a result. In 75 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for VSTM turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 37 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VSTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. VSTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.237) is normal, around the industry mean (3.498). P/E Ratio (-3.447) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (7.446) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VSTM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company that discovers and develops drugs
Industry Biotechnology